ADAPTIMMUNE THERAPEUTICS-ADR (ADAP) Institutional Ownership

None of the superinvestors we track currently report ADAPTIMMUNE THERAPEUTICS-ADR (ADAP) in their latest SEC Form 13F filings.

13F filings cover institutional equity holdings and are reported quarterly with a delay. This stock may still have insider Form 4 activity or appear in future filings.

When tracked funds report positions in ADAPTIMMUNE THERAPEUTICS-ADR (ADAP), this page will show 13F-reported ownership trends, hedge fund exposure, portfolio concentration, historical 13F filings, and estimated holding performance.

Institutional Ownership Trend

Portfolio quarterInstitutional holdersTotal reported valueTotal shares
Q3 20251$527,0324,054,089
Q2 20251$451,3201,882,860
Q1 20251$357,3311,813,860
Q4 20241$1,361,0372,526,524
Q3 20241$1,574,4081,656,575
Q2 20241$1,741,5021,786,341
Q1 20241$2,1991,391,775
Q4 20231$1,0871,370,239
Q3 20231$8021,027,860
Q2 20231$1,3931,506,375
Q1 20231$199182,700
Q4 20221$819560,973
ADAP Institutional Ownership and 13F Activity | InsiderSet